Discovery of Potent and Orally Bioavailable Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for the Treatment of Osteosarcoma
Xiaojing Chen,Lu Liu,Peng Liu,Yingying Chen,Dan Lin,Hao Yan,Qi Yan,Yi Wang,Yinda Qiu,Bo Fang,Huijing Huang,Jianchang Qian,Yunjie Zhao,Zhou Du,Qianwen Zhang,Xiaokun Li,Xiaohui Zheng,Zhiguo Liu
DOI: https://doi.org/10.1021/acs.jmedchem.1c01732
IF: 8.039
2022-03-03
Journal of Medicinal Chemistry
Abstract:Platelet-derived growth factor receptors (PDGFRs) are now considered promising targets for the treatment of osteosarcoma. Herein, the design, synthesis, and structure-activity relationships (SAR) of novel pyrimidine-2,4-diamine derivatives that selectively inhibit PDGFRα/β kinases have been studied. The screening cascades revealed that <b>7m</b> was the preferred compound among these derivatives, with IC<sub>50</sub> values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. Moreover, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) experiment revealed that <b>7m</b> has a substantial cytotoxic effect against all osteosarcoma cancer cell lines; <b>7m</b> also displayed robust antitumor effects and low toxicity in a xenograft model. Additionally, <b>7m</b> showed excellent bioavailability (<i>F</i> = 62.9%), suitable half-life (<i>T</i><sub>1/2</sub> = 2.12 h), satisfactory metabolic stability, and weak CYP isoform inhibitory activity, suggesting that <b>7m</b> is a potential drug candidate for PDGFR-driven osteosarcoma.
chemistry, medicinal